AB Life

AB LIFE GLOBAL

PRODUCT INFORMATION

FACE COLLECTION

Kbelle



ULTRA

Hyaluronic acid dermal filler



MID

HA 20 mg/mL
1 mL × 1 syringe

Product information for medical professionals



SOFT

ULTRA / MID / SOFT

www.ablife-global.com

Kbelle Product Applicable Areas




ULTRA



MID



SOFT



A clear portfolio

Source specifications, reorganised for comparison

FACE / 1 mL × 1 syringe

Specification	Soft	Mid	Ultra
HA (mg/mL)	20	20	20
Particle size	200 µm	350 µm	450 µm
Needle gauge	30G	27G	25G
Needle length	13 mm	13 mm	13 mm

Source lists ultra-thin-wall needles for all three face variants.

BODY / 10 mL × 1 syringe



Classic-H



Classic-S


Specification	Classic-H	Classic-S
HA (mg/mL)	20	20
Particle size	400 µm	250 µm
Cannula	20-21G / 50 mm	21-23G / 50 mm

Microbead architecture

MCL: Multi Staged Crosslinking, as named in the source

A structural concept

The source describes a crosslinked HA microbead structure. The original process diagram is reproduced below without changing its geometry.



Existing Cross-linking technology

Technology in existing HA filler


Primary or Secondary cross-linking can be different in each company.



Ultrafine bead divided by molecule of HA



New bead united by ultrafine bead




Another bead united by new bead



Kbelle Ultra

Material appearance



K’belle Ultra
Semi-solid gel state

Source photograph. The appearance and schematic structure do not establish clinical performance or duration.

Evidence in context

Distinguishing source descriptions from verified claims

Quality information in the source

Raw material

The leaflet names Shiseido Co., Ltd. and references the European Pharmacopoeia.

Process


The leaflet describes DVS and MDAWO washing technology, with a stated purity of 97% or more.

Documentation

Current certificates, test reports and market-specific authorisations should be reviewed separately.

Duration comparison in the source

Historical schematic redrawn for legibility. The 1-3 year scale is a source illustration, not a confirmed clinical duration for this product.



Source comparison / particle size and concentration


	Product “P”	K’belle
Particle size	1,000 µm	450 µm
HA	20 mg/mL	20 mg/mL

Material characterisation

Bench observations are not clinical safety or efficacy findings

Raw material and finished product

The original spectral comparison is reproduced as a source observation. Method, units and full test report require confirmation.



No conclusion of "no harm" or "100% unchanged HA" is drawn from this chart.

Hydrophilicity / centrifuge test

Source conditions: 3,000 rpm for 30 minutes; 1 cc sample in 500 cc water. Full protocol and comparator identities are not provided.

Sample	A	B	C	K'belle
Remaining	4 cc	4 cc	4.5 cc	15.5 cc

Values transcribed from the source illustration. This is a bench result, not a claim of injected volume gain.